GlassScriptPhysician profile
Melanie Mooney
NPI 1861462970
$3,191.21
in general payments reported to CMS, 2019-2025
33 companies · $557 in 2025
The $557 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $470 · 2020: $523 · 2021: $294 · 2022: $206 · 2023: $525 · 2024: $616 · 2025: $557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,698.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,697.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $618.22 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $546.33 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $384.57 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $273.13 | 2019-2025 | Farxiga, Airsupra |
| Amgen INC. | $213.50 | 2020-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.20 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $94.46 | 2023-2025 | |
| Exact Sciences Corporation | $93.68 | 2023-2024 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $82.84 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $58.91 | 2025 | Gemtesa |
| Allergan, INC. | $57.35 | 2019-2020 | |
| Abbott Laboratories | $51.29 | 2022-2023 | Freestyle Libre 3 |
| Dexcom, INC. | $50.95 | 2024-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $49.43 | 2021-2022 | |
| Glaxosmithkline, LLC. | $46.25 | 2024-2025 | Trelegy Ellipta |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.46 | 2019-2020 | |
| Esperion Therapeutics, INC. | $30.09 | 2022-2024 | Nexletol |
| Sequel Med Tech, LLC | $28.42 | 2025 | Twiist |
| Amarin Pharma, INC. | $27.59 | 2020-2021 | |
| Boston Scientific Corporation | $25.22 | 2025 | General - Pain Management |
| Astellas Pharma US INC | $22.70 | 2024 | Veozah |
| Idorsia Pharmaceuticals US INC | $21.78 | 2023 | Quviviq |
| Ars Pharmaceuticals Operations, INC. | $21.61 | 2025 | Neffy |
| Lifescan, INC. | $21.20 | 2023 | |
| Abiomed | $16.13 | 2025 | |
| Phathom Pharmaceuticals, INC. | $15.71 | 2025 | Voquezna |
| Ibsa Pharma INC. | $15.70 | 2023 | Tirosint, Licart |
| Pbg Puerto Rico LLC | $15.64 | 2021 | |
| Emd Serono, INC. | $15.04 | 2019 | |
| Merck Sharp & Dohme LLC | $13.91 | 2020 | |
| Arbor Pharmaceuticals, INC. | $12.31 | 2019 | |
| Abbvie INC. | $11.85 | 2022 | |
| Daiichi Sankyo INC. | $11.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melanie Mooney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.